Corvus Presents Updated Biomarker and Clinical Results from

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
17
Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference

BURLINGAME, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the presentation of updated biomarker and clinical results from its two lead programs that target the adenosine pathway, CPI-444, an adenosine A2A receptor antagonist, and CPI-006, an anti-CD73 antibody. The data were presented by Stephen Willingham, Ph.D., Senior Scientist at Corvus, at the Immuno-Oncology 360° Conference in New York during the “Discovery & Preclinical Science Plenary” session, which focused on tumor microenvironment changing technologies, pegylated cytokines and additional discovery and preclinical data.

Key CPI-444 Biomarker Results Dr. Willingham’s presentation, titled “Blockade of the Adenosine Pathway: Preclinical, Translational and Clinical Studies with CPI-444, an A2A Receptor Antagonist for Cancer Treatment,” reviewed gene expression data of an adenosine gene signature recently announced by Corvus (or AdenoSig), in patients with renal cell carcinoma (RCC) who are participating in Corvus’ ongoing Phase 1/1b study of CPI-444, a selective and potent inhibitor of the adenosine A2A receptor. In particular, the data from the study showed a relationship of this novel biomarker to angiogenesis gene expression data (or angiogenesis signature). Such findings indicate that expression of AdenoSig was inversely related to the angiogenesis signature, which has been well studied by others and correlates with response to vascular endothelial growth factor receptor (VEGFR) inhibitors such as Sutent® (sunitib malate) and other tyrosine kinase inhibitors. Low expression of angiogenesis genes predicts a lack of response to VEGFR inhibition. These data suggest that patients with a high AdenoSig are potentially more likely to respond to treatment with CPI-444 and less likely to respond to VEGFR inhibitors.

“Based on these translational data, we expect that we may be able to use the AdenoSig as a predictive biomarker to identify patients for adenosine pathway inhibition and select patients for future trials of CPI-444,” said Dr. Willingham. “The gene expression data also may enable us to select the optimum patients for combination therapy with CPI-006, our anti-CD73 antibody, which has demonstrated unique immunologic activity in early clinical trials.”

Key CPI-006 Clinical Results Dr. Willingham also presented updated clinical results from the ongoing Phase 1/1b dose-escalation study of CPI-006 in  patients with a variety of advanced cancers, including non-small cell lung cancer (NSCLC), RCC and other cancers who have failed standard therapies. The first arm of the study is evaluating CPI-006 as a monotherapy, a second arm is evaluating CPI-006 in combination with CPI-444, and a third arm is planned to evaluate CPI-006 in combination with pembrolizumab, an anti-PD-1 antibody. In particular, the updated results demonstrated that:

  • CPI-006 given as a monotherapy activated B cells and led to a redistribution of these cells along with changes in other immune cells (e.g., changes in T helper to T suppressor ratios). These data are consistent with immune stimulation induced by CPI-006.
  • CPI-006 reacted with an epitope on CD73 that led to blockade of adenosine production and expression of lymphocyte activation antigens that are independent of adenosine. 

“We continue to advance our two lead therapeutic programs that target the adenosine-cancer pathway. We believe we are well positioned for a potential pivotal trial of CPI-444 in renal cell carcinoma and other tumors based on the biomarker signature we discovered, and CPI-006 is beginning to show early signs of immunologic activity that may be important in cancer therapy,” said Richard A. Miller, M.D., an oncologist and co-founder, president and chief executive officer of Corvus. “Regarding our third pipeline program, we anticipate starting a Phase 1/1b trial of CPI-818, an ITK inhibitor for T-cell lymphoma, during the first quarter of 2019.”

About CD73 and Adenosine CD73 is a cell surface enzyme whose function is to convert adenosine monophosphate (AMP) to adenosine by removing phosphate from AMP. CD73 is expressed on cells of the immune system, including T-cells and B-cells. CD73 is also present on many tumors, including lung, renal, melanoma, colon, prostate, breast and others. In the tumor microenvironment, CD73 produces adenosine, which binds to the adenosine A2A receptor on immune cells and inhibits various immune responses including those directed against the tumor. Tumors utilize this immunosuppressive mechanism to escape attack by the immune system.

About CPI-006 CPI-006 is a potent humanized monoclonal antibody that reacts with the active site of CD73, blocking the conversion of AMP to adenosine. In vitro studies of CPI-006 have shown it is capable of substantially inhibiting the production of adenosine by blocking the CD73 enzyme and leads to activation of peripheral blood B cells.

About CPI-444 CPI-444 is a small molecule, oral, checkpoint inhibitor designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of adenosine in the tumor microenvironment to the A2A receptor. Adenosine, a metabolite of ATP (adenosine tri-phosphate), is produced within the tumor microenvironment where it may bind to the adenosine A2A receptor present on immune cells and block their activity. CD39 and CD73 are enzymes on the surface of tumor cells and immune cells. These enzymes work in concert to convert ATP to adenosine. In vitro and preclinical studies have shown that dual blockade of CD73 and the A2A receptor may be synergistic.

About Corvus Pharmaceuticals  Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidate, CPI-444, a small molecule inhibitor of the A2A receptor, is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s atezolizumab, an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. In May 2017, Corvus and Genentech expanded the collaboration and are now conducting a trial of CPI-444 and atezolizumab in patients with non-small cell lung cancer (NSCLC) who have failed prior therapies with anti-PD-(L)1 and platinum-based chemotherapy. Corvus is evaluating a second product candidate, CPI-006, a humanized monoclonal antibody directed against CD73, in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. For more information, visit www.corvuspharma.com.

FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements, including statements related to the potential safety and efficacy of CPI-444 and CPI-006, the Company’s ability to develop and advance product candidates into and successfully complete preclinical studies and clinical trials, including the Company’s Phase 1/1b clinical trial of CPI-444, the Company’s Phase 1/1b clinical trial of CPI-006, and the Company’s IND-enabling studies of CPI-818, the basis for and time of any future clinical trials of CPI-818, and the utility of biomarker data collected, including in relation to the adenosine gene signature. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 1, 2018, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of CPI-444 and CPI-006; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials; the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its preclinical studies of CPI-818; the Company’s ability to utilize biomarker data, including to identify patients more likely to respond to treatment with CPI-444 ; the results of preclinical studies may not be predictive of future results; the unpredictability of the regulatory process; and regulatory developments in the United States and foreign countries. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. 650-900-4522 LLea@corvuspharma.com

MEDIA CONTACT: Sheryl Seapy W2O pure 213-262-9390 sseapy@purecommunications.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 64

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 148

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 112

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Thread AI Joins Microsoft Pegasus: Big AI Leap

Updated Category News Views 26

Thread AI Leaps Ahead with Microsoft Partnership There's excitement in the air as Thread AI joins forces with Microsoft by entering the exclusive Pegasus Program. In the ever-evolving world of AI, making a splash this big doesn't happen every day. People in the tech alley are buzzing, and it looks like Thread AI is ready to rumble on a larger stage—much like a scrappy...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 86

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading

Top 5 Most Recently Viewed Articles

Evogene Partners with Academic Leader to Combat Metabolic Disorders

Updated Category News Views 174

Evogene's Innovative Collaboration Evogene Ltd. (NASDAQ: EVGN) has entered into an exciting partnership with Professor Ehud Gazit from Tel Aviv University to develop innovative therapeutics aimed at metabolic diseases. Understanding Metabolic Diseases Metabolic diseases often arise from the inability of the body to break down specific metabolites. This inability can lead...

Continue Reading
Farasis Energy's Rise in Solid-State Battery Rankings Explained

Updated Category News Views 505

Farasis Energy's Notable Achievement in Battery Technology Recently, Farasis Energy gained recognition as a leading contender in the 2024 China Solid-State Battery Competitiveness Rankings, marking a significant milestone in the company's journey. As a global frontrunner in electric vehicle (EV) battery solutions, Farasis Energy has established robust partnerships with...

Continue Reading
Building a Reliable Future with Weilliptic's Advanced AI

Updated Category News Views 310

Weilliptic: Pioneering Autonomous and Trustworthy AI In the rapidly evolving landscape of technology, Avinash Lakshman, a serial entrepreneur renowned for creating Amazon Dynamo and Apache Cassandra, is leading the charge towards a new foundational infrastructure that merges AI and blockchain into a cohesive and verifiable framework. This innovative platform, known as...

Continue Reading
Navigating Investor Rights: Aehr Test Systems Case Insights

Updated Category News Views 169

Aehr Test Systems Investor Rights and Securities Fraud Lawsuit Investors in Aehr Test Systems (NASDAQ: AEHR) find themselves at a critical juncture. The Rosen Law Firm, renowned for its advocacy on behalf of investors, has issued important reminders regarding a securities fraud lawsuit that centers on Aehr Test Systems. Understanding the Class Period The timeline for this...

Continue Reading
Understanding Andersons' Earnings and Market Performance Insights

Updated Category News Views 276

Anticipating Earnings from Andersons Inc Andersons Inc (NASDAQ: ANDE) is gearing up to share its quarterly earnings report soon. This announcement is of considerable interest to both existing shareholders and potential investors. It's vital to stay informed about what to expect before the company reveals its financial results. Projected Earnings and Market Sentiments...

Continue Reading